Total Funding
70
44
Total FundingPost-IPO Equity raised
Growth Score
-11 pts
Heat Score
-31 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
16018
Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.
Eugene A. Bauer: Co-Founder & Chief Medical OfficerPast Role: Dermira, Founder & Chief Medical Officer- Gregory Moss: Chief Business and Legal Officer, Corporate Secretary, and Chief Compliance OfficerPast Role: Kadmon, Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer
About the Company
Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed at
combating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles.
